Estimated Control (100%) Closed Transaction verified GlaucomaOphthalmic PharmaceuticalsOphthalmologyPharmaPharmaceuticals
Aerie Pharmaceuticals, Inc. acquired by Alcon Research, Ltd.
Alcon Research, Ltd. acquired Aerie Pharmaceuticals, Inc., a US ophthalmic pharmaceuticals brand, on Aug 22, 2022.
Transaction summary
- Target
- Aerie Pharmaceuticals, Inc.
- Acquirer
- Alcon Research, Ltd.
- Seller
- Aerie Pharmaceuticals, Inc. shareholders
- Announced
- 2022-08-22
- Geography
- United States
- Tags
- GlaucomaOphthalmic PharmaceuticalsOphthalmologyPharmaPharmaceuticals
- Type
- Acquisition
- Deal type
- Control
- Stake acquired
- 100%
- First added
- 2026-08-08
- Latest update
- 2026-08-08
Value and multiples
100% enterprise value
USD 750M
100% enterprise value | USD
Basis: Public source
Reported price is assumed to be 100% EV unless stated otherwise. Partial-stake estimates are qualified in the basis notes.
EV / revenue
4.4x
Period not stated
Basis: FundComb estimate
EV / EBITDA
-
EBITDA basis not stated
Basis: FundComb estimate
Basis
- USD 750m enterprise value is treated as publicly disclosed or derived directly from public source data.
- Valuation covers 100% of the target; the amount invested or paid for a stake is separate.
- EV / revenue: 4.4x.
- Revenue and multiple inputs are not fully disclosed in public transaction materials reviewed; treat the multiple as an estimate.
- No calculated multiple performed; the user-supplied 4.4x EV/sales multiple is retained. Implied revenue of approximately $170.5M ($750M / 4.4) is derived but not source-supported, so revenue_amount is left null.
Source summary
No public source summary has been published for this transaction yet.